Replies to post #86320 on Biotech Values

[zipjet]

Palo Alto increased their MNTA holdings by 9% to ~1,084,000.

That is a shift from reducing their holdings last quarter.

ij

[DewDiligence]

MNTA Major Shareholders

[Updated for SEC filings through 1/26/10.]


The table below shows all shareholders with a 5%+ stake
and all insiders with a 1%+ stake based on SEC filings on
Form 13G and Form 4, respectively. Insider holdings are
accurate as of today and include restricted stock and options,
whether or not vested. Non-insider holdings are as of 12/31/08
unless otherwise indicated. (Form 13G filings for holdings as
of 12/31/09 are due on 2/14/10.)

The percentages shown below are based on 49.1M diluted
shares (#msg-42163809), and hence they differ from the
percentages reported in SEC Form 13G filings.

 
                             Shares  Stake 
 Novartis                  4,708,679  9.6% 
 T Rowe Price              4,468,373‡ 9.1% 
 Visium Asset Mgmt         3,349,122  6.8% 
 Craig Wheeler (CEO)         987,344  2.0% 
 Alan  Crane (Director)      652,202  1.3% 
 G. Venkataraman (SVP, R&D)  628,540  1.2%  
 Ram Sasisekharan (Director) 492,344  1.0%  
  
 ‡As of 10/31/09 (from 13G/A filing 11/10/09).